FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224221738> ?p ?o ?g. }

• W4224221738 endingPage "12" @default.
• W4224221738 startingPage "1" @default.
• W4224221738 abstract "BACKGROUND: Patients with migraine, particularly with multiple prior preventive treatment failures, often have high rates of acute headache medication use and are at risk for overuse (acute or symptomatic headache medication use between 10 and 15 days per month [depending on the medication] for > 3 months). Furthermore, these patients have greater health care resource utilization (HCRU). OBJECTIVE: To examine acute headache medication use and HCRU with galcanezumab compared with placebo in a population with multiple prior migraine preventive treatment failures. METHODS: In the 3-month double-blind phase, patients with episodic or chronic migraine and treatment failures to 2 to 4 standard-of-care migraine preventive categories (lack of effectiveness or safety/tolerability) received galcanezumab 120 mg/month (following a 240-mg loading dose) or placebo; an optional 3 month open-label phase followed. Acute headache medication use (monthly days with acute headache medication utilization) was self-reported daily. The change from baseline in monthly days with acute headache medication used a mixed-model repeated measures analysis. HCRU was reported at baseline (for the previous 6 months) and at monthly visits. Migraine-related HCRU rates were evaluated in the total population per 100 patient-years. RESULTS: Of the 462 patients (galcanezumab n=232, placebo n=230), baseline mean days/month of acute headache medication was 12.3; 44.8% had acute headache medication overuse. Across months 1-3, least squares (LS) mean reductions in acute headache medication use were greater for the galcanezumab group (4.2) compared with placebo (0.9); the LS mean difference was 3.4 (95% CI = 2.7-4.1; P < 0.0001). Greater reductions in the galcanezumab group were observed as early as month 1; statistical separation continued at months 2 and 3 (all P < 0.0001). During the open-label phase, reductions from baseline ranged from 4.7 to 5.3 days and were similar in patients who transitioned from placebo to patients continuing galcanezumab. Reductions from baseline of migraine-specific health care visits (double-blind phase) were numerically greater with galcanezumab than placebo (215.5 vs 155.3). Patients switching to galcanezumab had reductions (212.9 days) similar to patients continuing galcanezumab (222.6 days). Migraine-specific emergency department visits decreased by two-thirds at month 3 in the galcanezumab group compared with nearly no reduction in the placebo group that experienced a similar reduction during the open-label phase. For both groups, migraine-specific hospitalizations were less than 2 per 100 patient-years. CONCLUSIONS: These results demonstrate that galcanezumab has the potential to reduce acute headache medication use and overuse and HCRU in patients with prior migraine preventive treatment failures. DISCLOSURES: Data were presented in part as a poster presentation at the 14th European Headache Congress (European Headache Federation), Virtual Meeting, July 3-5, 2020. Dr Ambrosini is on the advisory board for Eli Lilly and Company and received honorarium from Teva, Novartis, and Eli Lilly and Company. Dr Estemalik is on the advisory boards for Eli Lilly and Company, Lundbeck, and Allergan and the speakers' bureau for Teva, Lundbeck, Eli Lilly and Company, Allergan, and Biohaven. He received consulting fees from Eli Lilly and Company, Teva, Lundbeck, and Allergan and support for attending meetings and/or travel from Eli Lilly and Company, Allergan, Biohaven, Teva, and Lundbeck. Dr Pascual received research support from Instituto de Salud Carlos III, Ministry of Economy, Spain. He was also on advisory boards for Allergan, Amgen-Novartis, Eli Lilly and Company, and Stendhal and received consulting fees or honoraria from Allegan, Eli Lilly and Company, Novartis-Amgen, and Teva. Dr Rettiganti is an employee of Eli Lilly and Company and/or one of its subsidiaries, Indianapolis, IN. She is also a minor stock and restricted stockholder of Eli Lilly and Company. Mr. Stroud and Ms. Day are employees of Eli Lilly and Company and/or one of its subsidiaries, Indianapolis, IN. Dr Ford is an employee of and holds stock of Eli Lilly and Company and/or one of its subsidiaries, Indianapolis, IN. She also received support for attending meetings and/or travel from Eli Lilly and Company." @default.
• W4224221738 created "2022-04-26" @default.
• W4224221738 creator A5030119786 @default.
• W4224221738 creator A5040917727 @default.
• W4224221738 creator A5044344836 @default.
• W4224221738 creator A5046253395 @default.
• W4224221738 creator A5049595040 @default.
• W4224221738 creator A5061864796 @default.
• W4224221738 creator A5085373670 @default.
• W4224221738 date "2022-04-22" @default.
• W4224221738 modified "2023-10-02" @default.
• W4224221738 title "Changes in acute headache medication use and health care resource utilization: Results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER)" @default.
• W4224221738 cites W1982183874 @default.
• W4224221738 cites W1993579510 @default.
• W4224221738 cites W1994776902 @default.
• W4224221738 cites W2005239637 @default.
• W4224221738 cites W2023102259 @default.
• W4224221738 cites W2029991935 @default.
• W4224221738 cites W2038152559 @default.
• W4224221738 cites W2039274897 @default.
• W4224221738 cites W2048175760 @default.
• W4224221738 cites W2057556593 @default.
• W4224221738 cites W2075240722 @default.
• W4224221738 cites W2103671128 @default.
• W4224221738 cites W2136324281 @default.
• W4224221738 cites W2149233088 @default.
• W4224221738 cites W2167719770 @default.
• W4224221738 cites W2286833286 @default.
• W4224221738 cites W2493682340 @default.
• W4224221738 cites W2769724041 @default.
• W4224221738 cites W2883086901 @default.
• W4224221738 cites W2898072840 @default.
• W4224221738 cites W2900579548 @default.
• W4224221738 cites W2902418797 @default.
• W4224221738 cites W2919152931 @default.
• W4224221738 cites W2922174162 @default.
• W4224221738 cites W2939790627 @default.
• W4224221738 cites W2954031825 @default.
• W4224221738 cites W2968435022 @default.
• W4224221738 cites W2970814103 @default.
• W4224221738 cites W3145200805 @default.
• W4224221738 cites W3206076334 @default.
• W4224221738 cites W4234186222 @default.
• W4224221738 cites W4248061236 @default.
• W4224221738 doi "https://doi.org/10.18553/jmcp.2022.21375" @default.
• W4224221738 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35451858" @default.
• W4224221738 hasPublicationYear "2022" @default.
• W4224221738 type Work @default.
• W4224221738 citedByCount "3" @default.
• W4224221738 countsByYear W42242217382023 @default.
• W4224221738 crossrefType "journal-article" @default.
• W4224221738 hasAuthorship W4224221738A5030119786 @default.
• W4224221738 hasAuthorship W4224221738A5040917727 @default.
• W4224221738 hasAuthorship W4224221738A5044344836 @default.
• W4224221738 hasAuthorship W4224221738A5046253395 @default.
• W4224221738 hasAuthorship W4224221738A5049595040 @default.
• W4224221738 hasAuthorship W4224221738A5061864796 @default.
• W4224221738 hasAuthorship W4224221738A5085373670 @default.
• W4224221738 hasConcept C126322002 @default.
• W4224221738 hasConcept C142724271 @default.
• W4224221738 hasConcept C160735492 @default.
• W4224221738 hasConcept C162324750 @default.
• W4224221738 hasConcept C1862650 @default.
• W4224221738 hasConcept C197934379 @default.
• W4224221738 hasConcept C204787440 @default.
• W4224221738 hasConcept C27081682 @default.
• W4224221738 hasConcept C2778375690 @default.
• W4224221738 hasConcept C2778541695 @default.
• W4224221738 hasConcept C2781385661 @default.
• W4224221738 hasConcept C2908647359 @default.
• W4224221738 hasConcept C2910587157 @default.
• W4224221738 hasConcept C42219234 @default.
• W4224221738 hasConcept C50522688 @default.
• W4224221738 hasConcept C535046627 @default.
• W4224221738 hasConcept C71924100 @default.
• W4224221738 hasConcept C99454951 @default.
• W4224221738 hasConceptScore W4224221738C126322002 @default.
• W4224221738 hasConceptScore W4224221738C142724271 @default.
• W4224221738 hasConceptScore W4224221738C160735492 @default.
• W4224221738 hasConceptScore W4224221738C162324750 @default.
• W4224221738 hasConceptScore W4224221738C1862650 @default.
• W4224221738 hasConceptScore W4224221738C197934379 @default.
• W4224221738 hasConceptScore W4224221738C204787440 @default.
• W4224221738 hasConceptScore W4224221738C27081682 @default.
• W4224221738 hasConceptScore W4224221738C2778375690 @default.
• W4224221738 hasConceptScore W4224221738C2778541695 @default.
• W4224221738 hasConceptScore W4224221738C2781385661 @default.
• W4224221738 hasConceptScore W4224221738C2908647359 @default.
• W4224221738 hasConceptScore W4224221738C2910587157 @default.
• W4224221738 hasConceptScore W4224221738C42219234 @default.
• W4224221738 hasConceptScore W4224221738C50522688 @default.
• W4224221738 hasConceptScore W4224221738C535046627 @default.
• W4224221738 hasConceptScore W4224221738C71924100 @default.
• W4224221738 hasConceptScore W4224221738C99454951 @default.
• W4224221738 hasLocation W42242217381 @default.
• W4224221738 hasLocation W42242217382 @default.
• W4224221738 hasOpenAccess W4224221738 @default.
• W4224221738 hasPrimaryLocation W42242217381 @default.

• next